Sector News

Epstein leaves Novartis as pharmaceuticals splits in two

May 18, 2016
Life sciences

Novartis has announced plans to divide its pharmaceuticals division into two business units, in a restructure that also sees the departure of current division head and chief executive David Epstein.

Under the new structure, Novartis Pharmaceuticals and Novartis Oncology will form the Innovative Medicines Division at the Swiss drugmaker, joining the firm’s generics/biosimilars unit Sandoz and eye unit Alcon.

The move brings some key changes at the top: Epstein has decided to leave Novartis “and explore new challenges from the US”; Paul Hudson, currently executive vice president, North America, at AstraZeneca, will lead Novartis Pharmaceuticals; and Bruno Strigini, currently head of Novartis’ oncology segment, will also lead the Novartis Oncology business unit.

The firm said it expects that the changes, which ride on the back of the successful integration of the oncology assets from GlaxoSmithkline, will help drive its growth and innovation strategy, “with an increased focus and improved execution” for both business units.

Last year the group sold off its animal health division to Eli Lilly and vaccines unit to GSK, while bringing on board GSK’s oncology assets, under a drive to streamline focus and operations.

“A split makes sense because oncology now has critical mass, following the GSK deal, and oncology is in many ways becoming a differentiated business from the rest of pharmaceuticals,” said Mick Cooper, an analyst at equity research firm Trinity Delta, reports Reuters.

By Selina McKee

Source: Pharma Times

comments closed

Related News

May 26, 2024

From pharma to food: Vitafoods 2024 highlights

Life sciences

Beyond the vibrant displays and insightful discussions at Vitafoods 2024 stood the backdrop of a rapidly expanding nutraceutical market. With consumers increasingly seeking preventive healthcare solutions and natural alternatives to traditional medicine, the global nutraceutical industry has witnessed remarkable growth in recent years.

May 26, 2024

Genmab completes acquisition of ProfoundBio

Life sciences

Genmab has completed its $1.8 billion acquisition of ProfoundBio, a clinical-stage biotechnology company developing next-generation antibody-drug conjugates (ADC)s and ADC technologies for the treatment of cancers.

May 26, 2024

Merck to acquire life science company Mirus Bio

Life sciences

Merck has agreed to acquire US life sciences company Mirus Bio for $600 million (around €550 million) from Gamma Biosciences, a life sciences platform established by global investment firm KKR. Based in Madison, Wisconsin, Mirus Bio is a specialist in the development and commercialization of transfection reagents.

How can we help you?

We're easy to reach